Българска кардиология (Oct 2021)

Anticoagulation ant antiplatеlet therapy in patients with COVID-19 infection

  • Zheyna Cherneva,
  • Radostina Cherneva

DOI
https://doi.org/10.3897/bgcardio.27.e64222
Journal volume & issue
Vol. 27, no. 3
pp. 24 – 29

Abstract

Read online Read online Read online

COVID-19 infection is characterized with hyperstimulated infl ammatory response that affects lungs, cytokine storm and acute respiratory distress syndrome. Thrombotic complications are the leading reason for death in COVID-19 patients. Those of them with previous cardio-vascular diseases or risk factors – obesity, arterial hypertension, diabetes mellitus, advanced age are with higher risk for worse clinical outcome. Coagulopathy as well as thrombocytopathy and endothelial dysfunction are signifi cant pathophysiological factors for the severe clinical course of the infection. Beside anticoagulation therapy, targetеd strategies regarding thrombocytopathy and endothelial dysfunction are necessary for the treatment of patients with COVID-19 infection.

Keywords